The retinoblastoma protein--from bench to bedside.
The retinoblastoma tumour suppressor protein (Rb) has come a long way since its initial discovery in 1986. Encoded by the first candidate tumour suppressor gene it has emerged a versatile and context-dependent modulator of cell behaviour. Its activity is managed by signalling networks sensing intra- and extracellular cues. These cues are relayed to hold or permit inactivation of Rb by phosphorylation. Loss or mutation of the retinoblastoma gene is rare in sporadic cancers but defects in the pathways that license inactivation of Rb are found in the majority of them, suggesting that loss of Rb control is central to tumour development and arguing that its reinstatement might reverse tumour formation. Furthermore, mouse models with engineered defects in the Rb-phosphorylating kinases provide evidence that moderation of Rb inactivation may be a strategy for the prevention of tumour formation. The rationale behind these arguments, their underlying molecular concepts and strategies towards therapeutic application will be discussed.
Mittnacht
Sibylle
S
Cancer Research UK Centre for Cell and Molecular Biology, ICR, 237 Fulham Road, London SW3 6JB, UK. sibylle.mittnacht@icr.ac.uk
D000818:Animals; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology*; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000628:therapy; D016160:Retinoblastoma Protein / Q000235:genetics* / Q000502:physiology*
D016160:Retinoblastoma Protein